Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

BACKGROUND: There are limited therapeutic options to slow the progression of autosomal dominant polycystic kidney disease (ADPKD). Recent clinical studies indicate that somatostatin analogues are promising for treating polycystic liver disease and potentially also for the kidney phenotype. We report...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Meijer, Esther, Drenth, Joost P.H., d’Agnolo, Hedwig, Casteleijn, Niek F., de Fijter, Johan W., Gevers, Tom J., Kappert, Peter, Peters, Dorien J.M., Salih, Mahdi, Soonawala, Darius, Spithoven, Edwin M., Torres, Vicente E., Visser, Folkert W., Wetzels, Jack F.M., Zietse, Robert, Gansevoort, Ron T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4042404/
https://ncbi.nlm.nih.gov/pubmed/24342522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.ajkd.2013.10.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados